EFFICIENCY OF GESTATIONAL AND PERINATAL PATHOLOGY PREVENTION WITH A CYTOKINE-LIKE PEPTIDE IN FREQUENTLY RECURRING HERPES AT THE PREGRAVID STAGE

Abstract

Objective. To evaluate the efficiency of pregravid and antenatal antiviral immunomodulatory therapy for moderate and severe recurrent herpes in preventing gestational and perinatal complications. Subjects and methods. According to the prevention method, 414 women with recurrent herpes infection (HI) were divided into three groups. The efficiency of anti-relapse therapy was objectified by the effect size for therapy intervention in terms of the results of monitoring the indicators of immunity, the course of pregnancy, the status of fetoplacental blood flow and the health of newborn infants. Results. Step-by-step prophylactic treatment according to the developed method contributes to the normalization of adaptive and innate immunity indicators, to a significant decrease in the frequency of recurrent HI, pregnancy complications, intrauterine infection and the prevention of HI in newborn infants (the average number of patients needed to treat was 3 [95% confidence interval (CI), 2-4, p = 0.004]; odds ratio (OR) 0.03 [95% CI, 0.004-0.18, p < 0.001]. Conclusion. The pre-gestational use of a cytokine-like peptide with antiherpetic activity optimizes gestational and perinatal outcomes and prevents congenital herpes.